NEW RAY MEDIC (06108) announced its full-year results for the period ending December 31, 2025. Revenue reached approximately HK$130 million, representing an increase of about 38.9% year-on-year. The net loss attributable to the company's owners was about HK$20.1 million, a decrease of roughly 35.2% compared to the previous year. The loss per share was HK11.94 cents. The reduction in net loss was primarily attributed to the absence of an inventory impairment loss of approximately HK$13.1 million, which was recorded in the 2024 financial year for slow-moving inventory nearing its expiration date. Additional factors contributing to the improved result included a decrease in promotion costs of about HK$2.1 million, a reduction in marketing service fees of around HK$3.7 million, and a decrease in the amortization of prepayments for distribution rights of approximately HK$2.1 million (2024 financial year: approximately HK$3.5 million).